Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 44,805 restricted stock units (RSUs) to 20 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2025. The RSUs were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans four years, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE) ha annunciato l'assegnazione di 44.805 unità azionarie vincolate (RSU) a 20 nuovi dirigenti non esecutivi. Il comitato per la remunerazione ha approvato questi premi nell'ambito del Piano di Incentivazione all'Assunzione di Ultragenyx, con data di assegnazione il 16 maggio 2025. Le RSU sono state concesse come incentivo all'assunzione in conformità con la Regola 5635(c)(4) del Nasdaq. Il piano di maturazione prevede una durata di quattro anni, con il 25% delle azioni che maturano annualmente nell'anniversario della data di assegnazione, a condizione che l'impiego continui.
Ultragenyx Pharmaceutical (NASDAQ: RARE) anunció la concesión de 44,805 unidades restringidas de acciones (RSU) a 20 nuevos oficiales no ejecutivos. El comité de compensación aprobó estas adjudicaciones bajo el Plan de Incentivos de Empleo de Ultragenyx, con fecha de concesión el 16 de mayo de 2025. Las RSU se otorgaron como incentivos laborales en cumplimiento con la Norma 5635(c)(4) de Nasdaq. El calendario de adquisición se extiende por cuatro años, con un 25% de las acciones que se adquieren anualmente en el aniversario de la fecha de concesión, condicionado a la continuidad del empleo.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 20명의 신임 비임원 임원에게 44,805개의 제한 주식 단위(RSU)를 부여했다고 발표했습니다. 보상 위원회는 2025년 5월 16일부로 Ultragenyx 고용 유인 계획에 따라 이 상여를 승인했습니다. RSU는 Nasdaq 상장 규칙 5635(c)(4)를 준수하여 고용 유인책으로 부여되었습니다. 베스팅 일정은 4년에 걸쳐 진행되며, 매년 부여일 기념일에 25%의 주식이 베스팅되며, 계속 고용 조건이 충족되어야 합니다.
Ultragenyx Pharmaceutical (NASDAQ : RARE) a annoncé l'attribution de 44 805 unités d'actions restreintes (RSU) à 20 nouveaux cadres non exécutifs. Le comité de rémunération a approuvé ces attributions dans le cadre du Plan d'Incitation à l'Emploi d'Ultragenyx, avec une date d'attribution fixée au 16 mai 2025. Les RSU ont été accordées en tant qu'incitations à l'emploi conformément à la règle 5635(c)(4) du Nasdaq. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % des actions acquises chaque année à l'anniversaire de la date d'attribution, sous réserve d'une continuité d'emploi.
Ultragenyx Pharmaceutical (NASDAQ: RARE) gab die Gewährung von 44.805 Restricted Stock Units (RSUs) an 20 neu eingestellte nicht geschäftsführende Führungskräfte bekannt. Der Vergütungsausschuss genehmigte diese Zuteilungen im Rahmen des Ultragenyx Employment Inducement Plans mit einem Zuteilungsdatum vom 16. Mai 2025. Die RSUs wurden als Anreiz zur Einstellung gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25 % der Aktien jährlich am Jahrestag des Zuteilungsdatums vesten, vorausgesetzt, die Beschäftigung wird fortgesetzt.
- None.
- None.
NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,805 restricted stock units of the company’s common stock to 20 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
What is the vesting schedule for RARE's May 2025 RSU grants?
How many restricted stock units did Ultragenyx (RARE) grant in May 2025?
Under which plan were Ultragenyx's May 2025 RSUs granted?
What is the purpose of RARE's May 2025 stock unit grants?
